Combating Tuberculosis Infection: A Forbidding Challenge

Area of Science:

• * Infectious Diseases and Microbiology
• * Drug Discovery and Development

Background:

• * Tuberculosis (TB) treatment has been hampered by primitive therapies and rising drug-resistant strains.
• * Existing treatments are lengthy (6+ months) and second-line options involve severe side effects.
• * Patient non-adherence due to perceived improvement exacerbates the drug resistance problem.

Purpose of the Study:

• * To highlight the urgent need for novel antitubercular drugs, particularly for drug-resistant TB.
• * To discuss the requirements for new TB drugs: efficacy against resistant strains, compatibility with other medications (including antivirals), affordability, and shorter treatment durations.
• * To introduce promising new drug candidates that may overcome current treatment limitations.

Main Methods:

• * Review of recent advancements and drug pipelines in tuberculosis therapeutics.
• * Analysis of the challenges posed by drug-resistant tuberculosis and limitations of current treatments.
• * Identification and preliminary evaluation of newly developed antitubercular agents.

Main Results:

• * Several new drugs, including bedaquiline, delamanid, and teixobactin, show promise in combating TB.
• * Teixobactin demonstrates notable efficacy against drug-resistant tuberculosis strains.
• * These emerging therapies offer potential for improved treatment outcomes and shorter regimens.

Conclusions:

• * The pipeline offers a significant advancement over decades of limited progress in TB treatment.
• * New drugs like teixobactin are crucial for addressing the global burden of drug-resistant TB.
• * Future TB therapies must be effective, safe, affordable, and shorter to improve patient adherence and outcomes.